Enzalutamide
VIDEO: Androgen receptor pathway inhibitors ‘have transformed’ prostate cancer management
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: Upfront use of PARP, ARPI combination may offer greater survival benefit
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: Immunotherapy may offer next big breakthrough in advanced prostate cancer
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: New targets sought for advanced prostate cancer treatment
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: PSMA PET imaging 'single most important advance' in advanced prostate cancer
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.
Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer
Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective study results.
Combination extends survival in metastatic prostate cancer
The addition of talazoparib to enzalutamide extended OS among men with metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.
VIDEO: Stopping enzalutamide has little effect on prostate cancer quality of life
In this video, Stephen Freedland, MD, discusses the results of the EMBARK study into high-risk, nonmetastatic biochemically recurrent prostate cancer, which he co-presented at ASCO Annual Meeting.
Health care professionals optimistic as tirzepatide approved for obesity treatment
An analysis of global conversations involving more than 1,600 health care professionals on social media in November has revealed collective optimism in response to the approval of a new weight-management option for adults with obesity.